[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischemic-cerebral-infarction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischemic-cerebral-infarction":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,66,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100635761","clinical-impact-of-using-improve-to-select-patients-for-carotid-revascularisation-100635761",false,"NCT07556887","Clinical Impact of Using IMPROVE to Select Patients for Carotid Revascularisation","Clinical Impact of the Use of IMPROVE for Selection of Patients for Carotid Revascularisation: a Randomized Controlled Multicentre Non-inferiority Trial in Symptomatic Patients With 30-99% Carotid Stenosis","IMPROVE","Inclusion Criteria:\n\n* Mentally competent\n* 18 years or older\n* Recent (\\\u003C30 days) stroke (modified Rankin scale ≤3) or TIA\n* Ipsilateral 30-99% atheromatous stenosis at the carotid bifurcation assessed using non-invasive imaging according to NASCET criteria\n* Life expectancy \\>5 years\n* Patient and stenosis are suitable for carotid revascularisation\n* Patient is agreeable to randomisation and willing to accept either IMPROVE-based or CAU-based selection method for carotid revascularisation\n\nExclusion Criteria:\n\n* Cardiac source of embolism\n* Carotid stenosis caused by non-atherosclerotic disease e.g. dissection, fibromuscular disease or neck radiotherapy.\n* MRI contra-indications\n* Pregnancy","ALL","18 Years",{"count":20,"type":21},613,"ESTIMATED","INTERVENTIONAL",[24],"NA","Narrowing of the carotid artery due to atherosclerosis with an unstable plaque can cause a stroke. Patients with carotid artery disease who have had a TIA or minor stroke and are at high risk of another stroke are often treated with surgery or stenting to remove the plaque. For lower-risk patients, medication alone is the better option, as surgery also carries risks. A new decision method, based on MRI detection of unstable plaques (IMPROVE), can better assess stroke risk and help determine which patients do or do not need surgery. We are investigating whether this method is at least as effective as the standard approach, which mainly considers the degree of narrowing. We expect that this new method will help reduce strokes and lower healthcare costs.\n\nPatients will be followed for several years to compare which method is better for health and costs.",[27,28,29,30,31,32,33,34,35,36],"Carotid Artery Stenosis Symptomatic","Ischemic Cerebral Infarction","Stroke Ischemic","Atheroscleroses","Stroke (CVA) or TIA","Stroke","Intraplaque Hemorrhage","TIA (Transient Ischemic Attack)","Atherosclerosis Cerebral Infarction","Carotid Arteriosclerosis",[38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Carotid Artery Stenosis","Transient Ischemic Attack","Ischemic Stroke","Atherosclerosis","Plaque Rupture","Revascularisation","Carotid Endarterectomy","Carotid Artery Stenting","Magnetic Resonance Imaging","Stroke Risk Prediction","Intraplaque hemorrhage","Clinical Decision Support","Randomized Controlled Mulitcentre Trial","Cost-Effectiveness Analysis","Optimal Medical Therapy","RECRUITING","2026-05-12",{"date":56,"type":57},"2026-05-15","ACTUAL",{"date":59,"type":57},"2026-03-31",{"date":61,"type":21},"2031-08-31",{"name":63,"class":64},"Maastricht University Medical Center","OTHER",10,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100611593","phase-3-ongericimab-injection-reducing-recurrence-of-ischemic-stroke-100611593","NCT07242599","Ongericimab Injection Reducing Recurrence of Ischemic Stroke","A Multicenter, Randomized, Open-label, Parallel-controlled, Event-driven, Blinded-endpoint Trial Evaluating the Efficacy and Safety of Ongericimab Injection in High-risk Stroke Patients With Intracranial or Extracranial Atherosclerotic Stenosis.","ORIS","Inclusion Criteria:\n\n* Obtaining informed consent；\n* Age ≥18 years；\n* Patients with ischemic stroke within 3 months( NIHSS\\\u003C15 before randomization);\n* Presence of ≥50% stenosis in major intracranial or extracranial arteries, and related to the symptoms of the current episode or the location of infarction；\n* LDL-C ≥ 70 mg\u002FdL (1.8 mmol\u002FL) at screening.\n\nExclusion Criteria:\n\n* History of cerebral hemorrhage at any time (microhemorrhages present only on SWI are not an exclusion criterion)\n* Hemorrhage or other pathological neurological conditions on baseline brain CT\u002FMRI (e.g., vascular malformations, tumors, abscesses, or common non-ischemic brain diseases like multiple sclerosis);\n* Presence of isolated sensory symptoms (e.g., numbness), isolated visual changes, or isolated dizziness or vertigo, but no evidence of recent infarction on baseline head CT or MRI;\n* Unable to complete the assessment of intracranial and extracranial arterial stenosis before randomization\n* mRS score≥2 before onset (based on assessment of medical history);\n* Stroke caused by angioplasty\u002Fvascular surgery;\n* Cardioembolic stroke caused by atrial fibrillation, artificial heart valves, endocarditis, mitral stenosis, sinus node dysfunction, etc.\n* Most recent fasting triglycerides \\>400 mg\u002FdL (4.5 mmol\u002FL) prior to randomization;\n* Uncontrolled hypertension (SBP \\>180 mmHg or DBP \\>110 mmHg);\n* Hypothyroidism diagnosed within 1 month before randomization.\n* Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²);\n* Active liver disease or dysfunction (AST\u002FALT \\>3×ULN within 30 days pre-randomization);\n* NYHA Class III\u002FIV heart failure within 1 year prior to randomization;\n* Life-limiting non-cardiovascular diseases (life expectancy \\\u003C1 years);\n* Malignancy within 10 years (excluding adequately treated basal cell carcinoma, cervical CIS, DCIS, or stage 1 prostate cancer);\n* Known hypersensitivity to monoclonal antibody therapies;\n* PCSK9 inhibitor use within 3 months before randomization.\n* Participation in other drug\u002Fdevice trials within 30 days;\n* Women of childbearing potential without contraception, pregnancy, or lactation;\n* Inability to understand or comply with the study due to mental illness, cognitive, or emotional disorders, or other reasons deemed unsuitable for participation in the study by the investigator.",{"count":75,"type":21},4810,[77],"PHASE3","The Oris trial aims to evaluate whether the use of Ongericimab injection in patients with atherosclerotic ischemic cerebrovascular disease within 3 months of onset can reduce the risk of recurrent major cardiovascular events by achieving lower lipid-lowering target values (LDL-C \\\u003C 1.4 mmol\u002FL).",[28],[81,82,83,84],"ischemic stroke","lipid lowering therapy","Ongericimab Injection","LDL-C target","NOT_YET_RECRUITING","2026-04-15",{"date":88,"type":57},"2026-04-16",{"date":90,"type":21},"2026-04-22",{"date":92,"type":21},"2029-04-01",{"name":94,"class":64},"Beijing Tiantan Hospital",199,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100602252","phase-4-traditional-chinese-medicine-intervention-for-ischemic-cerebrovascular-disease-and-diabetes-mellitus-an-efficacy-comparative-study-100602252","NCT07121088","Traditional Chinese Medicine Intervention for Ischemic Cerebrovascular Disease and Diabetes Mellitus: An Efficacy Comparative Study","Comparative Effectiveness Study of Traditional Chinese Medicine Intervention in Ischemic Cerebrovascular Disease Comorbid With Diabetes Mellitus","TIDES","Inclusion Criteria:\n\n1. Age ≥ 18 years old, regardless of gender.\n2. Previously diagnosed with diabetes, or with an unknown medical history, meeting the WHO 2023 diagnostic criteria for type 2 diabetes, including any of the following:\n\n   * Fasting blood glucose ≥ 7.0 mmol\u002FL.\n   * 2-hour postprandial blood glucose ≥ 11.1 mmol\u002FL.\n   * Glycated hemoglobin ≥ 6.5%.\n3. Acute cerebral infarction meets the diagnostic criteria of \\*Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023\\*:\n\n   * Acute onset.\n   * Focal neurological deficits, with a few cases showing global neurological deficits.\n   * The presence of a responsible lesion on imaging or symptoms\u002Fsigns persisting for more than 24 hours.\n   * Exclusion of non-vascular etiologies.\n   * Exclusion of intracerebral hemorrhage by brain CT\u002FMRI.\n4. Onset of cerebral infarction \\\u003C 48 hours.\n5. TCM syndrome conforms to the \"toxin damaging brain collaterals\" syndrome (referring to the diagnostic criteria (draft) of \\*Research on the Diagnostic Criteria for the Syndrome of Mutual Binding of Stasis and Toxin in Ischemic Cardiovascular and Cerebrovascular Diseases\\* (Ju Jianqing et al., 2023)).\n6. Modified Rankin Scale (mRS) before onset: 0 - 1 point.\n7. National Institutes of Health Stroke Scale (NIHSS) at admission: 4 - 24 points.\n8. Signed informed consent form.",{"count":105,"type":21},3666,[107],"PHASE4","The objective of this observational study is to understand the long-term effects of traditional Chinese medicine (TCM) intervention on patients with cerebral infarction onset within \\\u003C48 hours and comorbid diabetes. The primary question it aims to address is:\n\nCan long-term TCM intervention for the treatment of ischemic cerebrovascular disease comorbid with diabetes improve patients' neurological deficits and self-care ability? Participants receiving TCM intervention (universal treatment combined with syndrome-specific treatment) as part of routine cerebrovascular disease management will undergo follow-up assessments at 30 days, 90 days, 6 months, and 12 months within 1 year to evaluate neurological status (e.g., mRS score, NIHSS score) and quality of life indicators.",[28,110],"Diabetes Mellitus",[112,113,114],"diabetes mellitus","ischemic cerebral infarction","Chuanzhitongluo capsule","2025-08-12",{"date":117,"type":57},"2025-08-13",{"date":119,"type":21},"2025-08-31",{"date":121,"type":21},"2027-12-31",{"name":123,"class":64},"Guangzhou University of Traditional Chinese Medicine"]